![]() ![]() The study included patients whose cancer cells produced high levels of PD-L1 as well as patients whose cancer cells produced low levels of PD-L1. More patients were alive after 2 years with Opdivo and ipilimumab treatment (64%) than with Opdivo alone (59%) or ipilimumab alone (45%). Patients given Opdivo plus ipilimumab lived for 11.5 months without their disease getting worse compared with 6.9 months for patients given only Opdivo and 2.9 months for patients given only ipilimumab. After an average follow-up of 24 months, 19% of patients who took Opdivo had a recurrence of their cancer or a new melanoma or had died, compared with 32% of patients given placebo.Ī fifth study in 945 previously untreated adults with advanced melanoma investigated Opdivo in combination with ipilimumab, Opdivo used alone or ipilimumab used alone. A fourth study in 790 adults with stage IIB or IIC melanoma who had surgery compared Opdivo with placebo (a dummy treatment). Patients treated with Opdivo lived on average 31 months before the cancer came back, or a new melanoma occurred or they died, compared with 24 months for patients treated with ipilimumab. Around 32% (38 out of 120) of patients given Opdivo responded to treatment and had a reduction in their tumours, compared with about 11% (5 out of 47) of patients given a treatment chosen by their doctor (dacarbazine or a combination of carboplatin and paclitaxel).Ī third study in 906 adults with stage IIIB, IIIC or IV melanoma who had surgery and who were at high risk of the cancer coming back compared Opdivo with ipilimumab. In the second study, 405 patients with advanced melanoma whose disease had got worse despite previous treatment with a cancer medicine were followed up for at least 6 months. The first study, involving 418 previously untreated advanced melanoma patients, found that patients treated with Opdivo lived longer than patients who received the cancer medicine dacarbazine: 73% of patients treated with Opdivo were alive after 12 months compared with 42% of patients given dacarbazine. Opdivo used on its own was studied in two main studies in adults with advanced melanoma who had not undergone surgery. Opdivo contains the active substance nivolumab. Opdivo can be used on its own and, for some cancers, it is also used together with other cancer medicines such as cabozantinib, ipilimumab or platinum-based chemotherapy. For some cancers, Opdivo can only be used if tests confirm that the cancer cells produce enough PD-L1. Opdivo works on cancer cells that produce a protein called PD-L1. Opdivo is mainly used when cancers that are advanced, unresectable (cannot be removed by surgery) or metastatic (have spread to other parts of the body) or when other treatments do not work.įor NSCLC that can be removed by surgery but is at high risk of coming back, Opdivo can also be given before surgery (neoadjuvant treatment).įor melanoma, oesophageal cancer, gastro-oesophageal junction cancer and urothelial cancer, Opdivo is also used to help prevent the cancer from coming back after patients have had surgery (adjuvant treatment). The medicine is used in adults for melanoma it is also used in adolescents from 12 years of age. gastric (stomach), gastro-oesophageal junction or oesophageal adenocarcinoma.oesophageal cancer and gastro-oesophageal junction cancer (cancer at the junction between the stomach and the oesophagus) after chemotherapy, radiotherapy and surgery. ![]() squamous oesophageal cancer (cancer of the oesophagus, the passage from mouth to stomach).a kind of cancer of the colon or rectum (lower part of the gut) that is described as microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR).malignant pleural mesothelioma (a cancer of the lining of the lungs).urothelial cancer, a cancer of the bladder and urinary tract.squamous cell cancer of the head and neck (SCCHN).classical Hodgkin lymphoma, a cancer of the lymphocytes (a type of white blood cell).advanced renal cell carcinoma, a kidney cancer.a lung cancer called non-small cell lung cancer (NSCLC).Opdivo is a cancer medicine used in adults to treat the following: ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |